Institutes,Country,Type,Name,Platform,Phase,Date started,Reference,"Listed by WHO, 05 Oct 2020","Listed by Milken, 05 Oct 2020",Other
Aegis Biodefense,USA,Commercial,DNA vaccine,DNA,Pre-clinical,09-06-20,NA (direct contact),no,no,NA
BioNet Asia,Thailand,Commercial,DNA vaccine,DNA,Pre-clinical,26-03-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,NA
Chula Vaccine Research Center,Thailand,Academic,DNA vaccine,DNA,Pre-clinical,31-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,DNA with electroporation
Ege University,Turkey,Academic,DNA vaccine,DNA,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Entos Pharmaceuticals,Canada,Commercial,Fusogenix DNA vaccine,DNA,Pre-clinical,19-03-20,https://www.pharmaceutical-business-review.com/news/entos-pharmaceuticals-fusogenix-covid-19/,yes,yes,NA
Genexine Consortium,Republic of Korea,Commercial,GX-19,DNA,Phase I/II,16-03-20,http://www.koreabiomed.com/news/articleView.html?idxno=7727,yes,yes,NA
Immunomic Therapeutics Inc/Epivax Inc/PharmaJet,USA,Commercial,DNA vaccine,DNA,Pre-clinical,09-04-20,https://www.immunomix.com/immunomic-therapeutics-forms-collaboration-with-epivax-and-pharmajet-to-develop-novel-vaccine-candidate-against-covid-19-using-its-investigational-unite-platform/,yes,yes,"Plasmid DNA, needle-free delivery"
Inovio Pharmaceuticals/International Vaccine Institute,USA/Republic of Korea,Commercial/Academic,INO-4800,DNA,Phase I/II,12-03-20,https://www.prnewswire.com/news-releases/inovio-receives-new-5-million-grant-to-accelerate-scale-up-of-smart-delivery-device-for-its-covid-19-vaccine-301022049.html,yes,yes,DNA plasmid vaccine electroporation device
Karolinska Intitute/Cobra Biologics,Sweden,Commercial/Academic,DNA vaccine,DNA,Pre-clinical,26-03-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,DNA with electroporation
Mediphage Bioceuticals/University of Waterloo,Canada,Commercial/Academic,msDNA vaccine,DNA,Pre-clinical,16-04-20,https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine,yes,yes,"Nasal spray, bacteriophage delivery, VLP-encoded DNA vaccine"
"National Research Centre, Egypt (DNA)",Egypt,Academic,DNA plasmid vaccine,DNA,Pre-clinical,28-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"S,S1,S2,RBD &N "
Osaka University/AnGes/Takara Bio,Japan,Commercial/Academic,AG0301-COVID19,DNA,Phase I/II,05-03-20,https://www.anges.co.jp/en/pdf.php?pdf=003Mk7IxCg7spYu6nteDj80QPMCznRi2.pdf,yes,yes,NA
Scancell/University of Nottingham/Nottingham Trent University,UK,Commercial/Academic,DNA vaccine,DNA,Pre-clinical,24-04-20,https://www.scancell.co.uk/Data/Sites/1/media/publications/news/covid-19-vaccine-programme.pdf,yes,yes,Target N and S proteins
Statens Serum Institute,Denmark,Academic,CoVAXIX,DNA,Pre-clinical,14-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,no,yes,NA
Symvivo,Canada,Commercial,bacTRL-Spike,DNA,Phase I,06-04-20,https://www.symvivo.com/covid-19,yes,yes,"Orally administered, genetically modified probiotic bacteria"
Takis/Applied DNA Sciences/Evvivax,Italy/USA,Commercial,DNA vaccine,DNA,Pre-clinical,27-01-20,http://www.takisbiotech.it/index.php/en/news/200-takis-and-evvivax-developing-a-2019-ncov-coronavirus-vaccine,yes,yes,NA
University of Cambridge/DIOSynVax,UK,Commercial/Academic,DIOS-CoVax2,DNA,Pre-clinical,17-01-20,https://www.cam.ac.uk/research/news/cambridge-research-team-working-towards-vaccine-against-covid-19,no,yes,NA
UW-Madison/Pan Genomes Systems,USA,Commercial/Academic,DNA vaccine,DNA,Pre-clinical,15-02-20,https://www.trialsitenews.com/uw-madison-spinoff-purses-covid-19-vaccine-introducing-pan-genome-systems/,no,no,Nasal spray; nucleic acid based
Zydus Cadila Healthcare Limited (DNA),India,Commercial,ZyCoV-D,DNA,Phase I/II,20-03-20,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,NA
Beijing Institute of Biological Products/Sinopharm,China,Commercial/Academic,BBIBP-CorV,Inactivated,Phase III,26-03-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,NA
Beijing Minhai Biotechnology Co Ltd,China,Commercial,Inactivated vaccine,Inactivated,Phase I,27-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Bharat Biotech/ICMR/National Institute of Virology,India,Commercial/Academic,COVAXIN,Inactivated,Phase I/II,30-06-20,https://timesofindia.indiatimes.com/city/hyderabad/indias-first-covid-19-vaccine-candidate-by-hyd-co-set-for-trials/articleshow/76699925.cms,yes,yes,NA
Erciyes University (inactivated),Turkey,Academic,Inactivated vaccine,Inactivated,Pre-clinical,24-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
"Institute of Medical Biology,/Chinese Academy of Medical Sciences",China,Academic,Inactivated vaccine,Inactivated,Phase I/II,17-04-20,https://www.biocentury.com/article/304515,yes,yes,NA
KM Biologics,Japan,Commercial,Inactivated vaccine,Inactivated,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Inactivated + alum
"National Research Centre, Egypt (inactivated)",Egypt,Academic,Inactivated vaccine,Inactivated,Pre-clinical,29-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Inactivated whole virus 
Osaka University/BIKEN/NIBIOHN (inactivated),Japan,Commercial/Academic,Inactivated vaccine,Inactivated,Pre-clinical,19-03-20,https://pj.jiho.jp/article/241725,yes,yes,NA
Research Institute for/Biological Safety Problems (inactivated),Republic of Kazakhstan,Academic,QAZCOVID-IN,Inactivated,Phase I/II,15-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Selcuk University (inactivated),Turkey,Academic,Inactivated vaccine,Inactivated,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Sinovac/Dynavax,China/USA,Commercial,Inactivated vaccine,Inactivated,Pre-clinical,16-04-20,https://www.globenewswire.com/news-release/2020/04/16/2017222/0/en/Dynavax-and-Sinovac-Announce-Collaboration-to-Develop-a-Coronavirus-COVID-19-Vaccine.html,yes,yes,Sinovac’s inactivated vaccine plus Dynavax adjuvant CpG 1018 adjuvant
Sinovac/Instituto Butantan,China/Brazil,Commercial/Academic,CoronaVac,Inactivated,Phase III,20-03-20,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,Formaldehyde-inactivated + alum
Valneva/Dynavax,France/USA,Commercial,Inactivated vaccine,Inactivated,Pre-clinical,22-04-20,https://valneva.com/press-release/valneva-and-dynavax-announce-collaboration-to-advance-vaccine-development-for-covid-19/,yes,yes,NA
Wuhan Institute of Biological Products/Sinopharm,China,Commercial/Academic,Inactivated vaccine,Inactivated,Phase III,26-03-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,NA
Codagenix/Serum Institute of India,USA/India,Commercial,Live-attenuated vaccine,Live-attenuated,Pre-clinical,13-02-20,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html?tc=eml_cleartime,yes,yes,Codon deoptimized live attenuated vaccines
Indian Immunologicals Ltd/Griffith University,India/USA,Commercial/Academic,Live-attenuated vaccine,Live-attenuated,Pre-clinical,23-04-20,https://news.griffith.edu.au/2020/04/23/griffith-university-researchers-on-the-road-to-covid-19-vaccine/,yes,yes,Codon deoptimized live attenuated virus
Mehmet Ali Aydinlar University/Abicadem Labmed Health Services,Turkey,Commercial/Academic,Live-attenuated vaccine,Live-attenuated,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Codon deoptimized live attenuated vaccines
Meissa Vaccines,USA ,Commercial,MV-014-210,Live-attenuated,Pre-clinical,30-06-20,https://www.businesswire.com/news/home/20200630005072/en/Meissa-Vaccines-Pipeline-Update-Vaccine-Candidates-COVID-19,no,yes,NA
Altimmune,USA,Commercial,T-COVID,Non-replicating viral vector,Pre-clinical,01-06-20,https://www.globenewswire.com/news-release/2020/06/01/2041361/0/en/Altimmune-Launches-Clinical-Trial-of-T-COVIDTM-an-Investigational-Intranasal-Immune-Modulator-for-the-Treatment-of-Patients-with-Early-COVID-19.html,yes,no,Adenovirus-based NasoVAX
Altimmune/University of Alabama at Birmingham,USA,Commercial/Academic,AdCOVID,Non-replicating viral vector,Pre-clinical,28-02-20,https://www.globenewswire.com/news-release/2020/02/28/1992600/0/en/Altimmune-Completes-First-Development-Milestone-Toward-a-Single-Dose-Intranasal-COVID-19-Vaccine.html,no,yes,Adenovirus-based NasoVAX expressing SARS2-CoV spike protein
Ankara University,Turkey,Academic,Non-replicating viral vector vaccine,Non-replicating viral vector,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Adenovirus-based
Bharat Biotech/Thomas Jefferson University,USA/India,Commercial/Academic,CORAVAX,Non-replicating viral vector,Pre-clinical,07-04-20,https://www.beckershospitalreview.com/infection-control/thomas-jefferson-university-researchers-develop-covid-19-vaccine-candidate.html,yes,yes,Killed rabies carrier vaccine
CanSino Biological Inc/Beijing Institute of Biotechnology,China,Commercial/Academic,Ad5-nCoV,Non-replicating viral vector,Phase III,20-01-20,https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials,yes,yes,NA
Centro Nacional Biotecnología (CNB-CSIC)/(vector),Spain,Academic,Non-replicating viral vector vaccine,Non-replicating viral vector,Pre-clinical,26-03-20,https://fems-microbiology.org/wp-content/uploads/2020/03/Enjuanes-Sola-Zúñiga-2020.-Novel-Human-Pathogenic-Coronavirus-SARS-CoV-2.pdf,yes,yes,MVA expressing structural proteins
DZIF - German Center for Infection Research/IDT Biologika GmbH,Germany,Commercial/Academic,MVA-S encoded vaccine,Non-replicating viral vector,Pre-clinical,11-04-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,MVA-S encoded
Erciyes University (vector),Turkey,Academic,Non-replicating viral vector vaccine,Non-replicating viral vector,Pre-clinical,23-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Adeno5 based
Gamaleya Research Institute,Russia,Academic,Gam-COVID-Vac,Non-replicating viral vector,Phase III,01-06-20,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"rAd26/rAd5 expressing S protein, intramuscular, separate trial of lyophilised formulation"
GeoVax,China,Commercial,MVA-VLP vaccine,Non-replicating viral vector,Pre-clinical,27-01-20,https://www.geovax.com/news/geovax-and-bravovax-wuhan-china-to-collaborate-on-development-of-coronavirus-vaccine,yes,yes,MVA-encoded VLP; formerly listed as GeoVax/BravoVax but collaboration did not proceed
Greffex,USA,Commercial,Ad5 S (GREVAX),Non-replicating viral vector,Pre-clinical,11-03-20,https://www.greffex.com/news/greffex-inc-completes-covid-19-vaccine-and-prepares-for-testing/,yes,yes,Ad5 S (GREVAX platform)
Icahn School of Medicine at Mount Sinai,USA,Academic,Non-replicating viral vector vaccine,Non-replicating viral vector,Pre-clinical,01-09-20,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Newcastle disease virus expressing S
ID Pharma,Japan,Commercial,Non-replicating viral vector vaccine,Non-replicating viral vector,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Sendai virus vector
IDIBAPS-Hospital Clinic (viral vector),Spain,Academic,MVA-S vaccine,Non-replicating viral vector,Pre-clinical,01-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
ImmunityBio Inc/NantKwest Inc,USA,Commercial,hAd5-COVID19-Spike/Nucleocapsid,Non-replicating viral vector,Pre-clinical,14-04-20,https://www.biospace.com/article/releases/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/,yes,yes,Four deletions enabling response in Ad-exposed
Institut Pasteur/TheraVectys,France,Commercial/Academic,Non-replicating viral vector vaccine,Non-replicating viral vector,Pre-clinical,01-02-20,http://www.theravectys.com/development-pipeline/,no,yes,Intranasal lentiviral vector vaccine
Janssen Pharmaceutical Companies,USA,Commercial,Ad26.COV2.S,Non-replicating viral vector,Phase III,27-01-20,https://www.cnbc.com/2020/01/27/jj-pretty-confident-it-can-create-china-coronavirus-vaccine.html,yes,yes,Ad26 (alone or with MVA boost)
Ludwig Maximilian University of Munich,Germany,Academic,MVA-SARS-2-S,Non-replicating viral vector,Phase I,27-03-20,https://www.en.uni-muenchen.de/news/newsarchiv/2020/sutter_impfstoffe_en.html,yes,no,Modified Caccinia virus Ankara vaccine
Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis,USA,Commercial/Academic,AAVCOVID,Non-replicating viral vector,Pre-clinical,05-05-20,https://masseyeandear.org/news/press-releases/2020/05/mee-and-mgh-advancing-aavcovid-vaccine,yes,yes,"adeno-associated viral (AAV)-based, S protein"
McMaster University,Canada,Academic,Non-replicating viral vector vaccine,Non-replicating viral vector,Pre-clinical,26-05-20,Direct contact,no,no,Multi-valent HuAd5 and ChAd68-vectored; aerosol delivery
National Center for Genetic Engineering &/Biotechnology (BIOTEC)/GPO,Thailand,Commercial/Academic,Non-replicating viral vector vaccine,Non-replicating viral vector,Pre-clinical,01-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant
"National Research Centre, Egypt (vector)",Egypt,Academic,Non-replicating viral vector vaccine,Non-replicating viral vector,Pre-clinical,30-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Influenza A H1N1 vector 
PLA Academy of Military Sciences,China,State,Ad5-nCoV,Non-replicating viral vector,Phase I,28-09-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Ad5 viral vector
ReiThera/Leukocare/Univercells,Italy,Commercial,GRAd-COV2,Non-replicating viral vector,Phase I,26-03-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,Replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S
Stabilitech Biophaarma Ltd,UK,Commercial,OraPro-COVID-19,Non-replicating viral vector,Pre-clinical,19-03-20,https://www.stabilitech.com/orapro-covid-19/,yes,yes,Orally administered recombinant adenovirus vector
Tsinghua University,China,Academic,Adenovirus-vectored vaccine,Non-replicating viral vector,Pre-clinical,02-04-20,http://www.china.org.cn/china/2020-04/02/content_75891534.htm,no,no,Adenovirus vector-based vaccine (could not verify if replicating/non-replicating)
University of Georgia/University of Iowa,USA,Academic,Non-replicating viral vector vaccine,Non-replicating viral vector,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Parainfluenza virus 5-based vaccine expressing S protein
University of Manitoba,Canada,Academic,Dendritic cell-based vaccine,Non-replicating viral vector,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
University of Oxford/AstraZeneca,UK,Commercial/Academic,ChAdOx1-S,Non-replicating viral vector,Phase III,10-01-20,https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development,yes,yes,Chimpanzee adenovirus vector
Valo Therapeutics Ltd,Finland/USA,Commercial,Pan-Corona,Non-replicating viral vector,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Adenovirus-based + HLA-matched peptides
Vaxart,USA,Commercial,VXA-CoV2-1,Non-replicating viral vector,Phase I,18-03-20,http://www.globenewswire.com/news-release/2020/03/18/2002458/0/en/EMERGENT-BIOSOLUTIONS-SIGNS-DEVELOPMENT-AND-MANUFACTURING-AGREEMENT-WITH-VAXART-FOR-THEIR-EXPERIMENTAL-ORAL-VACCINE-CANDIDATE-FOR-CORONAVIRUS-DISEASE.html,yes,yes,NA
Vaxinz Inc/Institute Leloir Foundation/CONICET/(vector #1),Argentina/USA,Commercial/Academic,VXZ-11NS,Non-replicating viral vector,Pre-clinical,01-08-20,http://vaxinz.com,no,no,Direct contact; human adenoviral vector
Vaxinz Inc/Institute Leloir Foundation/CONICET/(vector #2),Argentina/USA,Commercial/Academic,VXZ-11PFS,Non-replicating viral vector,Pre-clinical,01-08-20,http://vaxinz.com,no,no,Direct contact; human adenoviral vector
Aivita Biomedical Inc,USA,Commercial,AV-COVID-19,Other,Phase I,13-05-20,https://clinicaltrials.gov/ct2/show/NCT04386252?term=vaccine&cond=COVID-19&draw=2&rank=18,no,no,NA
COVID-19 Vaccine Corporation Ltd,New Zealand,Commercial,Biodegradable polymer biobead display vaccine,Other,Pre-clinical,01-05-20,https://cvc.nz,no,no,2 antigens: RBD and multiple T cell epitopes
ERC Worldwide,Belgium,Commercial,ERC SARS-Cov-2 vaccine,Other,Pre-clinical,09-04-20,https://finance.yahoo.com/news/erc-launches-development-program-novel-120010871.html,no,no,Consists of virions at different stages of viral replication and human cells/fragments
Farmacológicos Veterinarios SAC/Universidad Peruana Cayetano Heredia/(bacterial vector),Peru,Commercial/Academic,Replicating bacterial vector vaccine,Other,Pre-clinical,28-08-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD
OSE immunotherapeutics,France,Commercial,T-cell based vaccine,Other,Pre-clinical,02-10-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,"CD8 T cell peptide targeting(S, M, N) and (NSPs) SARS-CoV-2 proteins"
Shenzhen Geno-Immune Medical Institute/(modified APC),China,Academic,aAPC vaccine,Other,Phase I,31-01-20,https://www.nature.com/articles/d41573-020-00073-5,no,yes,Artificial APCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins
Shenzhen Geno-Immune Medical Institute/(modified DC),China,Academic,LV-SMENP-DC vaccine,Other,Phase I,31-01-20,https://www.nature.com/articles/d41573-020-00073-5,no,yes,DCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific CTLs
Ufovax,USA,Commercial,1c-SApNP VLP vaccine,Other,Pre-clinical,12-04-20,https://statnano.com/news/67566/Ufovax-Formulates-COVID-19-Vaccine-Using-its-Nanoparticle-Vaccine-Technology,no,no,NA
"University of California, Los Angeles",USA,Academic,Replicating bacterial vector vaccine,Other,Pre-clinical,01-05-20,http://ucla.technologypublisher.com/techcase/20-0322,no,yes,Recombinant LVS ΔcapB – vectored vaccine expressing multiple SARS-CoV-2 antigens.
Versatope/Umass (OMV),USA,Commercial/Academic,rOMV vaccine,Other,Pre-clinical,30-03-20,https://www.uml.edu/News/stories/2020/M2D2-coronavirus-efforts.aspx?mc_cid=b01e8bd49c&mc_eid=565cb5181a,no,no,Recombinant outer membrane vesicles displaying spike protein
Voltron Therapeutics/Hoth Therapeutics/Massachusetts General Hospital,USA,Commercial/Academic,HaloVax,Other,Pre-clinical,27-03-20,https://www.biospace.com/article/releases/halovax-announces-agreement-with-hoth-therapeutics-to-joint-develop-a-self-assembling-vaccine-sav-to-protect-patients-at-risk-of-coronavirus-covid-19-infection/,no,yes,VaxCelerate platform
AdaptVac,Denmark,Commercial,Capsid-like particle vaccine,Protein subunit,Pre-clinical,09-03-20,https://www.medizin.uni-tuebingen.de/files/view/W0nPpDMa6lLgzbJo9VGLXAbO/200309%20Press%20release%20Covid-19%20consortium_final.pdf,yes,yes,Capsid-like particle
Adimmune Corporation,Taiwan,Commercial,AdimrSC-2f,Protein subunit,Phase I,09-03-20,https://www.taiwannews.com.tw/en/news/3894294,no,no,RBD produced by baculovirus-insect cell expression system; administered with/without aluminum content as adjuvant
AJ Vaccines,Denmark,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,06-03-20,https://ajvaccines.com/news/,yes,yes,S protein
Akers Biosciences/Premas Biotech ,USA,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,08-04-20,https://www.biospace.com/article/releases/akers-biosciences-and-premas-biotech-announce-successful-expression-of-coronavirus-antigens/,no,no,"Spike (S), Envelope (E) and Membrane (M) proteins"
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,China,Commercial/Academic,RBD-Dimer vaccine,Protein subunit,Phase II,02-03-20,http://hefeihightech.chinadaily.com.cn/2020-03/02/c_459323.htm,yes,yes,Adjuvanted recombinant protein (RBD-Dimer)
AnyGo Technology,China,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Protein subunit, recombinant S1-Fc fusion protein"
Applied Biotechnology Institute Inc,USA,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Orally delivered, heat stable subunit"
Axon Neuroscience SE,Slovakia,Commercial,Peptide vaccine,Protein subunit,Pre-clinical,09-04-20,https://www.biospace.com/article/releases/axon-neuroscience-has-a-promising-peptide-vaccine-against-covid-19-in-development/,yes,yes,NA
Baiya Phytopharm/Chula Vaccine Research Center,Thailand,Commercial/Academic,Plant-based vaccine,Protein subunit,Pre-clinical,01-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Plant-based subunit; RBD-Fc + Adjuvant
Baylor College of Medicine,USA,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,20-03-20,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,S1 or RBD protein
BioFarma/Eijkman Institute for Molecular Biology,Indonesia,State/Academic,Merah Putih,Protein subunit,Pre-clinical,14-08-20,https://en.antaranews.com/news/154250/bio-farma-projected-covid-19-vaccine-merah-putih-roll-out-by-2022,no,no,Recombinant forms of the S sub-units and N protein
Biological E Ltd,India,Commercial,RBD-based vaccine,Protein subunit,Pre-clinical,11-04-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,Adjuvanted protein subunit (RBD)
BiOMVis Srl/University of Trento,Italy,Commercial/Academic,OMV-based vaccine,Protein subunit,Pre-clinical,15-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,OMV-based vaccine
Bogazici University,Turkey,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Peptide + novel adjuvant
Chulalongkorn University/GPO,Thailand,Commercial/Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,01-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,RBD protein fused with Fc of IgG + Adjuvant
Clover Biopharmaceuticals Inc/GSK/Dynavax,China/UK/USA,Commercial,SCB-2019,Protein subunit,Phase I,24-02-20,https://www.businesswire.com/news/home/20200224005319/en,yes,yes,Native-like trimeric subunit spike protein vaccine
Covaxx/University of Nebraska Medical Center,USA,Commercial/Academic,UB-612,Protein subunit,Phase I,15-07-20,https://www.covaxx.com/press-release-jul15-1,no,yes,Multitope peptide-based Vaccine 
EpiVax,USA,Commercial,EPV-CoV-19,Protein subunit,Pre-clinical,27-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
EpiVax/University of Georgia,USA,Commercial/Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,04-03-20,https://epivax.com/news/press-release-epivax-accelerates-covid-19-vaccine-development-with-ugas-center-for-vaccines-and-immunology,yes,yes,S protein
ExpreS2ion,Denmark,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,06-03-20,"https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-eu-grant-award-for-the-covid-19-vaccine-development-programme,c3054055",yes,yes,Drosophila S2 insect cell expression system and AdaptVac capsid VLPs
Farmacológicos Veterinarios SAC/Universidad Peruana Cayetano Heredia/(subunit),Peru,Commercial/Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,28-08-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,RBD protein (baculovirus production) + FAR-Squalene adjuvant
"FBRI SRC VB VECTOR,/Rospotrebnadzor, Koltsovo/(peptide)",Russia,State,EpiVacCorona,Protein subunit,Phase I/II,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Peptide vaccine
"FBRI SRC VB VECTOR,/Rospotrebnadzor, Koltsovo/(subunit)",Russia,State,Protein subunit vaccine,Protein subunit,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Subunit vaccine
Flow Pharma Inc,USA,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,26-03-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,NA
G+Flas Life Sciences,Republic of Korea,Commercial,Plant-based vaccine,Protein subunit,Pre-clinical,01-04-20,http://www.biospectator.com/view/news_view.php?varAtcId=9750,no,no,NA
Generex/EpiVax,USA/Canada,Commercial,Ii-Key peptide vaccine,Protein subunit,Pre-clinical,27-02-20,https://www.globenewswire.com/news-release/2020/02/27/1992098/0/en/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html,yes,yes,NA
Heat Biologics/University Of Miami,USA,Commercial/Academic,gp-96 vaccine,Protein subunit,Pre-clinical,05-03-20,https://www.heatbio.com/news-media/news-releases/detail/649/heat-biologics-announces-research-collaboration-with,yes,yes,NA
Helix Biogen Consult/Ogbomoso & Trinity Immonoefficient/Laboratory,Nigeria ,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,01-06-20,https://www.pulse.ng/news/local/covid-19-nigerian-scientists-working-on-preventive-vaccines-call-for-assistance/x256s7z,yes,yes,NA
iBio/CC-Pharming,USA/China,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,03-02-20,https://www.globenewswire.com/news-release/2020/02/03/1979068/0/en/iBio-and-CC-Pharming-Initiate-Joint-Development-of-Coronavirus-Vaccine.html,yes,yes,"Subunit protein, plant produced"
ImmunoPrecise/LiteVax BV,Canada,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,20-02-20,https://pipelinereview.com/index.php/2020022173854/Antibodies/ImmunoPrecise-Launches-Coronavirus-Vaccine-and-Therapeutic-Antibody-Program.html,yes,yes,NA
IMV Inc,USA,Commercial,DPX-COVID-19,Protein subunit,Pre-clinical,30-03-20,https://ir.imv-inc.com/press-releases/detail/638/imv-inc-provides-updates-on-the-development-of,yes,yes,Peptide antigens formulated in lipid nanoparticle formulation
InnoMedica,Switzerland,Commercial,TaliCoVax19,Protein subunit,Pre-clinical,19-04-20,https://www.innomedica.com/en/2020/03/30/march-2020-innomedica-launches-project-for-corona-vaccination/,no,yes,RBD protein expressed from bacteria + liposome carrier system
Innovax/Xiamen University/GSK,China/UK,Commercial/Academic,COVID-19 XWG-03,Protein subunit,Pre-clinical,03-04-20,https://www.fiercebiotech.com/biotech/gsk-allies-innovax-for-covid-19-vaccine-r-d-project,yes,yes,Truncated S (spike) proteins
Instituto Finlay de Vacunas,Cuba,State,FINLAY-FR-1,Protein subunit,Phase I/II,01-08-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,no,no,RBD + adjuvant
Intravacc/Epivax (peptide),Netherlands/USA,Commercial,OMV-peptide vaccine,Protein subunit,Pre-clinical,14-05-20,https://www.intravacc.nl/,yes,yes,NA
Intravacc/Epivax (subunit),Netherlands/USA,Commercial,OMV-subunit vaccine,Protein subunit,Pre-clinical,14-05-20,https://www.intravacc.nl/,yes,yes,NA
Izmir Biomedicine and Genome Center,Turkey,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Kentucky Bioprocessing Inc,USA,Commercial,KBP-COVID-19,Protein subunit,Phase I/II,02-04-20,https://www.kentucky.com/news/coronavirus/article241709386.html,yes,yes,Biotech subsidiary of British American Tobacco
LakePharma Inc,USA,Commercial,"Protein subunit, nanoparticle vaccine",Protein subunit,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Nanoparticle vaccine
Liaoning Chengda Biotechnology/Tsinghua University,China,Commercial/Academic,Peptide vaccine,Protein subunit,Pre-clinical,17-04-20,https://www.bioworld.com/COVID19products,no,no,NA
Lomonosov Moscow State University ,Russia,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,01-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Structurally modified spherical particles of the tobacco mosaic virus (TMV) 
Max Planck Institute of/Colloids and Interfaces (subunit),Germany,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,13-05-20,https://www.mpg.de/14807464/0511-mpin-116799-corona-vaccination-via-the-skin,no,yes,S protein plus targeting ligand for Langerhans cells
Medigen Vaccine Biologics Corporation/NAID/Dynavax,Taiwan/USA,Commercial/Academic,MVC-COV1901,Protein subunit,Phase I,17-02-20,https://www.pharmashots.com/press-releases/taiwan-firm-teams-up-with-us-to-develop-covid-19-vaccine/,yes,yes,S-2 P protein + CpG 1018
MIGAL Galilee Research Institute,Israel,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,27-02-20,http://www.migal.org.il/Migal.covid,yes,yes,Oral E. coli-based protein expression system of S and N proteins
MOGAM Institute for Biomedical Research/GC Pharma,Republic of Korea,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,19-03-20,http://www.businesskorea.co.kr/news/articleView.html?idxno=42991,yes,yes,Synthetic antigen-based ubunit vaccine
Mynvax,India,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,15-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
National Institute of Infectious Disease/Shionogi/UMN Pharma,Japan,Commercial/Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,11-04-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,S protein + adjuvant
"National Research Centre, Egypt (subunit)",Egypt,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Protein Subunit S,N,M&S1 protein "
Neovii/Tel Aviv University,Israel,Commercial/Academic,RBD-based vaccine,Protein subunit,Pre-clinical,13-05-20,https://neovii.com/neovii-partners-with-tel-aviv-university-to-develop-novel-covid-19-vaccine/,yes,yes,RBD-based 
Novavax,USA,Commercial,NVX-CoV2373,Protein subunit,Phase III,10-03-20,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,yes,yes,VLP-recombinant protein nanoparticle vaccine + Matrix M
Ohio State University/Kazakh National Agrarian University,USA/Republic of Kazakhstan,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,25-07-20,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,NA,NA,RBD protein delivered in mannose- conjugated chitosan nanoparticle
OncoGen,Romania,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,26-03-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,Synthetic long peptide vaccine candidate for S and M proteins
Osaka University/BIKEN/NIBIOHN (subunit),Japan,Commercial/Academic,VLP-recombinant protein vaccine,Protein subunit,Pre-clinical,11-04-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,VLP-recombinant protein + adjuvant
PDS Biotechnology,USA,Commercial,PDS0203,Protein subunit,Pre-clinical,16-04-20,https://www.globenewswire.com/news-release/2020/04/16/2017301/0/en/PDS-Biotechnology-Initiates-Novel-Vaccine-Development-Programs-For-COVID-19-and-Universal-Influenza-Delay-of-PDS0101-VERSATILE-002-trial.html,no,yes,Versamune T-cell activating technology with Sars-CoV-2 antigens
Quadram Institute Biosciences,UK,Commercial/Academic,OMV-based vaccine,Protein subunit,Pre-clinical,07-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Bacterial extracellular vesicle (BEV)-based mucosal vaccine. 
Research Institute for/Biological Safety Problems (subunit),Republic of Kazakhstan,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,31-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Sanofi Pasteur/GSK,France/UK,Commercial,Protein subunit vaccine,Protein subunit,Phase I/II,20-03-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,S protein (baculovirus production)
SK Biosciences,Republic of Korea,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,23-03-20,http://www.koreabiomed.com/news/articleView.html?idxno=7798,no,yes,NA
Soligenix Inc/University of Hawaiʻi at Mānoa,USA,Commercial/Academic,CiVax,Protein subunit,Pre-clinical,28-07-20,https://www.prnewswire.com/news-releases/soligenix-announces-publication-of-positive-pre-clinical-results-for-a-novel-covid-19-vaccine-301100798.html,no,no,Heat-stable subunit vaccine with CoVaccine adjuvant
Sorrento Therapeutics,USA,Commercial,T-VIVA-19,Protein subunit,Pre-clinical,17-08-20,https://sorrentotherapeutics.com/research/covid-19/t-viva-19/,no,yes,Recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc (T-VIVA-19)
St Petersburg Scientific Research Institute/of Vaccines and Sera,Russia,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,11-04-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,"Recombinant protein, nanoparticles (based on S-protein and other epitopes)"
University Hospital Tübingen,Germany,Academic,CoVac-1,Protein subunit,Phase I,01-09-20,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,SARS-CoV-2 HLA-DR peptides
University of Alberta,Canada,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Spike based
"University of California, San Diego",USA,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,20-04-20,https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine,no,yes,Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch
University of Pittsburgh,USA,Academic,PittCoVacc,Protein subunit,Pre-clinical,02-04-20,https://www.upmc.com/media/news/040220-falo-gambotto-sars-cov2-vaccine,yes,yes,Microneedle arrays S1 subunit
University of Queensland/CSL/Seqirus,Australia/UK/USA,Commercial/Academic,Molecular clamp vaccine,Protein subunit,Phase I,24-01-20,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,yes,yes,"Molecular clamp stabilized spike protein, CSL MF59 adjuvant"
University of San Martin/CONICET,Argentina,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,12-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
University of Virginia,USA,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,S subunit intranasal liposomal formulation with GLA/3M052 adjuvants
Vabiotech,Vietnam,State/Commercial,IC-BEVS,Protein subunit,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Protein subunit, recombinant S protein in IC-BEVS  "
Vaxil Bio,Israel,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,13-02-20,https://pipelinereview.com/index.php/2020021673805/Vaccines/Vaxil-Announces-the-Identification-of-a-Potential-Corona-Virus-Vaccine-and-Provides-an-Update-in-the-Previously-Announced-Debt-Financing.html,yes,yes,NA
Vaxine Pty/Medytox,Australia,Commercial,COVAX-19,Protein subunit,Phase I,03-04-20,https://news.flinders.edu.au/blog/2020/04/03/flinders-targets-covid-19-vaccine/,yes,yes,Recombinant spike protein with Advax™ adjuvant
Versatope/Umass (subunit),USA,Commercial/Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,30-03-20,https://www.uml.edu/News/stories/2020/M2D2-coronavirus-efforts.aspx?mc_cid=b01e8bd49c&mc_eid=565cb5181a,no,no,Polypeptide-based
"VIDO-InterVac,/University of Saskatchewan",Canada,Academic,Adjuvanted microsphere peptide,Protein subunit,Pre-clinical,20-03-20,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,NA
Walter Reed Army Institute of Research/USAMRIID,USA,Academic,Protein subunit vaccine,Protein subunit,Pre-clinical,05-03-20,https://www.defense.gov/Newsroom/Transcripts/Transcript/Article/2104736/defense-department-press-briefing-investigating-and-developing-vaccine-candidat/,yes,yes,S protein
"West China Hospital,/Sichuan University",China,Academic,Protein subunit vaccine,Protein subunit,Phase I,28-08-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,RBD (baculovirus production expressed in Sf9 cells)
Yisheng Biopharma,China,Commercial,Protein subunit vaccine,Protein subunit,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Aurobindo,India,Commercial,Replicating viral vector vaccine,Replicating viral vector,Pre-clinical,15-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,VSV-S
Beijing Wantai Biological Pharmacy/Xiamen University,China,Commercial/Academic,DelNS1-2019-nCoV-RBD-OPT1,Replicating viral vector,Phase I,09-09-20,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Intranasal flu-based-RBD
BIOCAD/IEM,Russia,Commercial,Replicating viral vector vaccine,Replicating viral vector,Pre-clinical,11-04-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)
DZIF - German Center for Infection Research/CanVirex AG,Germany,Commercial/Academic,Replicating viral vector vaccine,Replicating viral vector,Pre-clinical,26-03-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,"Measles virus (S, N targets)"
"FBRI SRC VB VECTOR,/Rospotrebnadzor, Koltsovo/(vector #1)",Russia,State,Replicating viral vector vaccine,Replicating viral vector,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Measles Vector
"FBRI SRC VB VECTOR,/Rospotrebnadzor, Koltsovo/(vector #2)",Russia,State,Replicating viral vector vaccine,Replicating viral vector,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Recombinant vaccine based on Influenza A virus, intranasal vaccine"
"FBRI SRC VB VECTOR,/Rospotrebnadzor, Koltsovo/(vector #3)",Russia,State,Replicating viral vector vaccine,Replicating viral vector,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Replicating viral vector; VSV vector
Fundação Oswaldo Cruz (FIOCRUZ)/Instituto Buntantan,Brazil,Academic,Replicating viral vector vaccine,Replicating viral vector,Pre-clinical,01-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Attenuated Influenza expressing an antigenic portion of the Spike protein
IAVI/Merck,USA,Commercial/Academic,V590,Replicating viral vector,Phase I,05-03-20,https://www.iavi.org/newsroom/press-releases/2020/iavi-and-batavia-announce-collaboration-vsv-vector-epidemic-preparedness-vaccines,yes,yes,Replication-competent VSV chimeric virus technology (VSVdeltaG) expressing Spike (S) glycoprotein
Institut Pasteur/Themis/University of Pittsburg/Merck,France/USA/Austria,Commercial/Academic,V591,Replicating viral vector,Phase I/II,19-03-20,https://www.themisbio.com/cepi-collaborates-with-the-institut-pasteur-in-a-consortium-to-develop-covid-19-vaccine/,yes,yes,Measles Vector
Intravacc/Wageningen Bioveterinary Research/Utrecht University,Netherlands/Germany,Commercial/Academic,NDV-SARS-CoV-2/Spike ,Replicating viral vector,Pre-clinical,14-05-20,https://www.intravacc.nl/,yes,yes,NA
Israel Institute for Biological Research/Weizmann Institute of Science,Israel,Academic,Replicating viral vector vaccine,Replicating viral vector,Pre-clinical,28-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
KU Leuven,Belgium,Academic,YF17D vector vaccine,Replicating viral vector,Pre-clinical,27-01-20,https://www.brusselstimes.com/all-news/belgium-all-news/92085/ku-leuven-researchers-near-test-phase-for-coronavirus-vaccine-wuhan-china-infection-virus-france/,yes,yes,Yellow fever vaccine backbone with SARS-CoV-2 spike protein
Lancaster University,UK,Academic,APM vector vaccine,Replicating viral vector,Pre-clinical,15-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Avian paramyxovirus vector (APMV) 
Sumagen/International Vaccine Institute,Republic of Korea,Commercial/Academic,VSV vector vaccine,Replicating viral vector,Pre-clinical,06-03-20,https://pulsenews.co.kr/view.php?year=2020&no=237416,no,no,VSV vector
Tonix Pharma/Southern Research,USA,Commercial,Horsepox vector vaccine,Replicating viral vector,Pre-clinical,24-03-20,https://ir.tonixpharma.com/press-releases/detail/1195/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year,yes,yes,Horsepox vector expressing S protein
University of Hong Kong,Hong Kong,Academic,Replicating viral vector vaccine,Replicating viral vector,Pre-clinical,26-03-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,Influenza vector expressing RBD
University of Western Ontario,Canada,Academic,VSV-S,Replicating viral vector,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Replicating viral vector; VSV-S
UW-Madison/FluGen/Bharat Biotech,USA/India,Commercial/Academic,CoroFlu,Replicating viral vector,Pre-clinical,02-04-20,https://www.pharmaceutical-technology.com/news/flugen-bharat-bio-uw-madison-covid-vaccine/,yes,yes,M2SR platform; self-limiting replication; intranasal
Zydus Cadila Healthcare Limited (vector),India,Commercial,Replicating viral vector vaccine,Replicating viral vector,Pre-clinical,20-03-20,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,Measles vector
Amyris Inc/Infectious Disease Research Institute,USA,Commercia/Academic,saRNA vaccine,RNA,Pre-clinical,27-07-20,https://investors.amyris.com/2020-07-27-Amyris-and-The-Infectious-Disease-Research-Institute-Partner-to-Advance-Novel-RNA-Vaccine-Platform-Beginning-With-COVID-19-Application,yes,no,saRNA formulated in a NLC
Arcturus/Duke-NUS,USA/Singapore,Commercial/Academic,LUNAR-COV19/ARCT-021,RNA,Phase I/II,04-03-20,https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-and-duke-nus-medical-school-partner,yes,yes,NA
BIOCAD,Russia,Commercial,RNA vaccine,RNA,Pre-clinical,19-03-20,https://biocadglobal.com/index.php?posts&post=45,yes,yes,NA
BioNTech/Fosun Pharma/Pfizer,Germany/USA,Commercial,BNT162,RNA,Phase III,17-03-20,https://www.businesswire.com/news/home/20200316005943/en/,yes,yes,NA
Cansino Biologics/Precision Nanosystems,China/Canada,Commercial,RNA vaccine,RNA,Pre-clinical,20-05-20,https://www.precisionnanosystems.com/our-company/news-room/detail/cansino-biologics-and-precision-nanosystems-announce-collaboration-to-co-develop-a-covid-19-rna-vaccine,yes,yes,LNP-mRNA
Centro Nacional Biotecnología (CNB-CSIC)/(RNA),Spain,Academic,RNA vaccine,RNA,Pre-clinical,26-03-20,https://fems-microbiology.org/wp-content/uploads/2020/03/Enjuanes-Sola-Zúñiga-2020.-Novel-Human-Pathogenic-Coronavirus-SARS-CoV-2.pdf,yes,yes,Replicating defective SARS-CoV-2 derived RNAs
Chimeron Bio/George Mason University ,USA,Commercial/Academic,RNA vaccine,RNA,Pre-clinical,28-05-20,https://www.businesswire.com/news/home/20200528005481/en/Chimeron-Bio-George-Mason-University%E2%80%99s-National-Center,no,yes,NA
China CDC/Tongji University/Stermina Therapeutics,China,Commercial/Academic,RNA vaccine,RNA,Pre-clinical,17-03-20,https://news.cgtn.com/news/2020-03-17/Shanghai-announces-steady-progress-in-COVID-19-vaccine-development--OVydZfNUFG/index.html,yes,yes,NA
Chulalongkorn University,Thailand/USA,Academic,ChulaCov19,RNA,Phase I/II,01-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,LNP-mRNA 
CureVac,Germany/USA,Commercial,CVnCoV,RNA,Phase II,03-03-20,https://www.curevac.com/news/curevac-ceo-daniel-menichella-berät-mit-us-präsident-donald-trump-und-mitgliedern-der-corona-task-force-entwicklungsmöglichkeiten-eines-coronavirus-impfstoffes,yes,yes,NA
Elixirgen Therapeutics/Fujita Health University,USA,Commercial/Academic,EXG-5003,RNA,Pre-clinical,04-06-20,https://elixirgentherapeutics.com/news/fda/elixirgen-therapeutics-concludes-pre-ind-meeting-with-fda-for-its-covid-19-vaccine-candidate-exg-5003,no,yes,NA
Emergex Vaccines/George Mason University,UK/USA,Commercial/Academic,RNA vaccine,RNA,Pre-clinical,22-04-20,https://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,no,yes,NA
eTheRNA Immunotherapies,Belgium,Commercial,mRNA TriMix vaccine,RNA,Pre-clinical,24-03-20,https://www.thepharmaletter.com/article/etherna-launches-consortium-and-starts-development-of-cov-2-mrna-vaccine,yes,yes,Intranasal
"FBRI SRC VB VECTOR,/Rospotrebnadzor, Koltsovo/(RNA)",Russia,State,RNA vaccine,RNA,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Fudan University/Shanghai JiaoTong University/RNACure Biopharma (VLP),China/USA,Commercial/Academic,RNA vaccine (encoding VLP),RNA,Pre-clinical,20-03-20,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,LNP-encapsulated mRNA cocktail encoding VLP
Fudan University/Shanghai JiaoTong University/RNACure Biopharma/(RBD),China/USA,Commercial/Academic,RNA vaccine (encoding RBD),RNA,Pre-clinical,20-03-20,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,LNP-encapsulated mRNA encoding RBD
GeneOne Life Science/Houston Methodist,USA,Commercial/Academic,RNA vaccine,RNA,Pre-clinical,17-03-20,https://www.houstonmethodist.org/research/covid19/geneone/,no,yes,NA
Gennova,India,Commercial,Self-amplifying RNA vaccine,RNA,Pre-clinical,15-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Greenlight Biosciences,USA,Commercial,RNA vaccine,RNA,Pre-clinical,05-05-20,https://www.greenlightbiosciences.com/covid19/,yes,yes,NA
IDIBAPS-Hospital Clinic (RNA),Spain,Academic,mRNA vaccine,RNA,Pre-clinical,01-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Imperial College London,UK,Academic,LNP-nCoVsaRNA,RNA,Phase I,15-01-20,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid-19-vaccine/,yes,yes,NA
Infectious Disease Research Institute/Amyris Inc,USA,Commercial/Academic,AMID-SC2,RNA,Pre-clinical,27-07-20,https://investors.amyris.com/2020-07-27-Amyris-and-The-Infectious-Disease-Research-Institute-Partner-to-Advance-Novel-RNA-Vaccine-Platform-Beginning-With-COVID-19-Application,no,no,Semi-synthetic squalene-based adjuvant
Max Planck Institute of/Colloids and Interfaces (RNA),Germany,Academic,RNA vaccine,RNA,Pre-clinical,13-05-20,https://www.mpg.de/14807464/0511-mpin-116799-corona-vaccination-via-the-skin,no,yes,S mRNA plus targeting ligand for Langerhans cells
Moderna/NIAID,USA,Commercial/Academic,mRNA-1273,RNA,Phase III,13-01-20,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,yes,yes,LNP-encapsulated mRNA
PLA Academy of Military Sciences/Walvax Biotech,China,Commercial/State,ARCoV,RNA,Phase I,17-04-20,https://www.biocentury.com/article/304515,yes,yes,NA
RNAimmune Inc,USA,Commercial,RNA vaccine,RNA,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Rochester Clinical Research,USA,Commercial,RNA vaccine,RNA,Pre-clinical,05-05-20,https://www.rcrclinical.com/clinical-trial/coronavirus-vaccine-interest-list/,no,no,NA
Selcuk University (RNA),Turkey,Academic,mRNA vaccine,RNA,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Translate Bio/Sanofi Pasteur,France/USA,Commercial,LNP-mRNA vaccine,RNA,Pre-clinical,27-03-20,https://investors.translate.bio/news-releases/news-release-details/sanofi-pasteur-and-translate-bio-collaborate-develop-novel-mrna,yes,yes,NA
University of Tokyo/Daiichi-Sankyo,Japan,Commercial/Academic,LNP-encapsulated mRNA vaccine,RNA,Pre-clinical,11-04-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,NA
University of Washington/NIH/HDT Bio Corp,USA,Commercial/Academic,HDT-301,RNA,Pre-clinical,13-02-20,https://newsroom.uw.edu/news/covid-19-vaccine-has-robust-response-nonhuman-primates,no,no,NA
Ziphius Therapeutics/Ghent University,Belgium,Commercial/Academic,ZIP-1642,RNA,Pre-clinical,20-03-20,https://7dffaa19-682b-4760-bc5a-592e63dfdd3b.filesusr.com/ugd/bc1b8f_b6bf5b2e693b4a14aaa51084089eb95c.pdf,no,yes,mRNA encoding multiple SARS-CoV-2 antigens
AbVision,USA,Commercial,AVI-205,Unknown,Pre-clinical,03-05-20,http://abvisioninc.com/2020/05/03/abvision-announced-a-first-in-class-active-targeting-vaccine-candidate-for-covid-19/,no,yes,NA
Adeleke University,Nigeria ,Academic,Unnamed vaccine,Unknown,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,no,yes,NA
Boryung Biopharma,Republic of Korea,Commercial,Unnamed vaccine,Unknown,Pre-clinical,09-03-20,http://www.koreabiomed.com/news/articleView.html?idxno=7650,no,no,NA
"Catholic University,/Millennium Institute of Immunology &/Immunotherapy",Chile,Academic,Unnamed vaccine,Unknown,Pre-clinical,13-03-20,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,no,yes,NA
Changchun Zhuoyi Biological,China,Commercial,Unnamed vaccine,Unknown,Pre-clinical,17-04-20,https://www.biocentury.com/article/304515,no,no,NA
Chongqing Zhifei Biological Products/Chinese Academy of Sciences,China,Commercial/Academic,Unnamed vaccine,Unknown,Pre-clinical,17-04-20,https://www.biocentury.com/article/304515,no,no,NA
City of Hope,USA,Academic,Unnamed vaccine,Unknown,Pre-clinical,24-03-20,https://www.cityofhope.org/breakthroughs/city-of-hope-researchers-developing-covid-19-vaccine,no,no,NA
Codiak BioSciences/Ragon Institute,USA,Commercial,Unnamed vaccine,Unknown,Pre-clinical,01-06-20,https://www.businesswire.com/news/home/20200601005079/en/Codiak-BioSciences-Collaborates-Ragon-Institute-Evaluate-exoVACC%E2%84%A2,no,yes,exoVACC exome platform
Hualan Biological Engineering,China,Commercial,Unnamed vaccine,Unknown,Pre-clinical,17-04-20,https://www.biocentury.com/article/304515,no,no,NA
ISR Immune System Regulation,Sweden,Commercial,ISR-50,Unknown,Pre-clinical,19-03-20,http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0,no,yes,NA
Nidovax,USA,Commercial,Unnamed vaccine,Unknown,Pre-clinical,28-06-20,https://www.nidovax.com/,no,yes,IMT504 technology
Oragenics,USA,Commercial,TerraCoV2,Unknown,Pre-clinical,04-05-20,https://www.oragenics.com/news-media/press-releases/detail/104/oragenics-acquires-noachis-terra-inc-to-develop-its,no,yes,NA
"Precision Vaccines Program,/Boston Children's Hospital",USA,Academic,Unnamed vaccine,Unknown,Pre-clinical,11-03-20,https://hms.harvard.edu/news/designing-coronavirus-vaccine,no,yes,NA
Royal (Wuxi) Biopharmaceutical ,China,Commercial,Unnamed vaccine,Unknown,Pre-clinical,17-04-20,https://www.biocentury.com/article/304515,no,no,NA
Shandong Buchang Pharma,China,Commercial,Unnamed vaccine,Unknown,Pre-clinical,12-02-20,https://fr.reuters.com/article/idUSP8N2A605E,no,no,NA
SmartPharm Therapeutics Inc/Sorrento Therapeutics,USA,Commercial,Gene-encoded antibody vaccine,Unknown,Pre-clinical,23-03-20,https://smartpharmtx.com/archives/7805,no,yes,NA
Tulane University,USA,Academic,Unnamed vaccine,Unknown,Pre-clinical,19-02-20,https://news.tulane.edu/pr/tulane-university-launches-new-coronavirus-research-program-develop-vaccine-and-advanced,no,yes,NA
United Biomedical/c19,Taiwan/USA,Commercial,Unnamed vaccine,Unknown,Pre-clinical,19-03-20,http://www.unitedbiomedical.com/COVID-19/covid-19.html,no,yes,NA
Vault Pharma/University of California Los Angeles,USA,Commercial/Academic,Unnamed vaccine,Unknown,Pre-clinical,01-06-20,https://www.businesswire.com/news/home/20200601005170/en/Coronavirus-Vaccine-Development-Underway-Vault-Pharma,no,yes,Nanoparticles (vaults) as second-line defense of infection
Verndari Inc/UC Davis,USA,Commercial/Academic,Unnamed vaccine,Unknown,Pre-clinical,29-04-20,https://www.verndariinc.com/news/4,no,yes,VaxiPatch single-dose dermal patch with a metal microneedle array
Vir Biotechnology/GSK,USA/UK,Commercial,Unnamed vaccine,Unknown,Pre-clinical,06-04-20,https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-enter-collaboration-find-coronavirus,no,yes,NA
Vivaldi Biosciences/Esco Aster,USA/Singapore,Commercial,Unnamed vaccine,Unknown,Pre-clinical,14-05-20,https://www.vivaldibiosciences.com/news-2/e4punpyr485q117deum1k1xrps4wjt,no,yes,Chimeric vaccine (coronavirus and influenza)
ZhongKe Biopharm ,China,Commercial,Unnamed vaccine,Unknown,Pre-clinical,17-04-20,https://www.biocentury.com/article/304515,no,no,NA
Zhongyi Anke Biotechnology ,China,Commercial,Unnamed vaccine,Unknown,Pre-clinical,17-04-20,https://www.biocentury.com/article/304515,no,no,NA
ARTES Biotechnology,Germany,Commercial,VLP vaccine,Virus-like particle,Pre-clinical,27-04-20,http://artes-biotechnology.biz/artes-joins-global-combat-against-corona/,yes,yes,NA
Bezmialem Vakif University,Turkey,Academic,VLP vaccine,Virus-like particle,Pre-clinical,21-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Doherty Institute,Australia,Academic,VLP vaccine,Virus-like particle,Pre-clinical,28-01-20,https://www.doherty.edu.au/our-work/institute-themes/viral-infectious-diseases/emerging-infections/2019-novel-coronavirus/about-2019-novel-coronavirus,yes,yes,NA
Imophoron Ltd/Bristol University,UK,Commercial/Academic,ADDomer VLP vaccine,Virus-like particle,Pre-clinical,08-03-20,https://www.pharmaceutical-technology.com/news/bristol-university-imophoron-covid-vaccine/,yes,yes,ADDomer multiepitope display
IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing Centre/Grifols,Spain,Commercial,VLP vaccine,Virus-like particle,Pre-clinical,28-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,S protein integrated in HIV VLPs
Mahidol University/GPO,Thailand,Academic,VLP vaccine,Virus-like particle,Pre-clinical,01-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Max Planck Institute,Germany,Academic,VLP vaccine,Virus-like particle,Pre-clinical,25-07-20,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
Medicago Inc/GSK/Dynavax,Canada/USA/UK,Commercial,Plant-derived VLP vaccine,Virus-like particle,Phase I,12-03-20,https://www.biospace.com/article/releases/medicago-announces-production-of-a-viable-vaccine-candidate-for-covid-19/,yes,yes,VLP (CoVLP) adjuvanted with GSK or Dynavax adjuvants
Middle East Technical University,Turkey,Academic,VLP vaccine,Virus-like particle,Pre-clinical,01-07-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Navarrabiomed Oncoimmunology group,Spain,Commercial,VLP vaccine,Virus-like particle,Pre-clinical,01-06-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Lentivirus and baculovirus vehicles 
OSIVAX,France,Commercial,VLP vaccine,Virus-like particle,Pre-clinical,05-05-20,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,VLP (COVID-19 and SARS1)
Saiba GmbH,Switzerland,Commercial,VLP vaccine,Virus-like particle,Pre-clinical,11-04-20,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,RBD displayed on VLPs
SpyBiotech/Serum Institute of India,UK/India,Commercial,RBD-HBsAg VLP vaccine,Virus-like particle,Phase I/II,05-06-20,https://www.gov.uk/government/news/india-joins-uks-global-vaccine-mission,yes,yes,SpyCatcher/SpyTag display technology
University of Sao Paulo,Brazil,Academic,VLP vaccine,Virus-like particle,Pre-clinical,18-03-20,https://www.efe.com/efe/english/portada/brazil-scientists-using-new-approach-in-search-for-covid-19-vaccine/50000260-4199376,yes,yes,NA
VBI Vaccines/National Research Council of Canada,USA,Commercial/Academic,VLP vaccine,Virus-like particle,Pre-clinical,31-03-20,https://www.businesswire.com/news/home/20200331005198/en/VBI-Vaccines-Announces-Collaboration-National-Research-Council,yes,yes,"Enveloped VLP pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS S proteins"
